BiotechTV - News

Episodes

Protagonist Therapeutics has two medicines in front of FDA right now - we discuss the expertise in peptide based drug development that has enabled them to get to this point

February 20, 2026

Protagonist Therapeutics' execs discuss their oral peptide platform, with two drugs at the FDA, and a pipeline targeting obesity and I&I.

NewLimit is using epigenetic reprogramming to bring cells back to a younger and healthier state, thus tackling age related disease

February 19, 2026

NewLimit is pioneering epigenetic reprogramming to make old cells function like young ones again, developing novel therapies for age-related diseases.

Gordian Biotechnology announced that it will be using its unique large-scale in vivo screening process to help Pfizer look for new targets against obesity

February 18, 2026

Gordian Biotech is using its high-throughput in vivo screening platform to help Pfizer discover new obesity targets, revolutionizing discovery.

Ocular Therapeutix Chair & CEO Pravin Dugel discusses the result of today's SOL-1 phase 3 superiority trial of AXPAXLI vs EYLEA in wet AMD

February 17, 2026

Ocular Therapeutix's AXPAXLI is the first drug to prove superiority over EYLEA in a landmark Phase 3 trial for wet AMD.

Oxford based Infinitopes raised an additional $15.4M in a second closing of its seed round to bring the total raised to $35.1M. It will have clinical data on its cancer vaccine by the end of the year

February 17, 2026

Infinitopes raises $15.4M, totaling $35.1M for its novel cancer vaccine. Clinical data on its unique immunopeptidomics tech is due by EOY.

Biotech CEOs discuss the state of the industry, what is needed to compete globally, the importance of having a patient-centric approach, and more

February 13, 2026

Biotech CEOs discuss a patient-centric approach, navigating policy and funding, and the need for collaboration to maintain global leadership.

Analyst Thursdays: Mizuho Senior Biotech Analyst Graig Suvannavejh shares his take on three key biotech trials that are scheduled to read out soon, and one that recently happened

February 12, 2026

Mizuho's Graig Suvannavejh on key biotech readouts: Ideaya in uveal melanoma, EyePoint in wet AMD, Palvella in rare skin disease & Corvus.

Upstream Bio's CEO Rand Sutherland discusses today's severe asthma data for verekitug, a TSLP receptor antagonist

February 11, 2026

Upstream Bio's verekitug shows strong Ph2 asthma data with 12-week dosing, but market reacts negatively to 24-week results. CEO discusses path to Ph3.

Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib

January 28, 2026

Corvus Pharma CEO discusses soquelitinib's promising atopic dermatitis data, highlighting its novel ITK inhibitor mechanism and durable effects.

SF Healthcare Week: Perceptive Advisors' Joe Edelman, one of the top investors in biotech, shares his investment philosophy and his take on the sector heading into 2026

January 17, 2026

Top biotech investor Joe Edelman shares his objective, probability-based investment philosophy, his bullish outlook for 2026, and key holdings.

SF Healthcare Week: Cytokinetics CEO Robert Blum discusses the approval and impending launch of the cardiomyopathy therapy MYQORZO

January 16, 2026

Cytokinetics' CEO discusses the launch of its cardiomyopathy drug MYQORZO, aiming to outcompete BMS with a differentiated, lighter REMS.

SF Healthcare Week: Sana Bio's CEO Steve Harr describes the science behind the company's cell therapy program that aims to be a cure for type 1 diabetes

January 16, 2026

Sana Bio's CEO details a potential cure for type 1 diabetes using gene-edited, immune-evasive stem cell-derived islets to end insulin need.

SF Healthcare Week: Neurocrine Biosciences CEO Kyle Gano describes how the company's novel muscarinic agonist portfolio is rooted in novel drug design, with its lead M4 agonist in late-stage trials

January 15, 2026

Neurocrine Biosciences' CEO discusses a strategy of leveraging core biology for new areas like obesity and advancing a selective M4 agonist.

SF Healthcare Week: Recursion's new CEO Najat Khan shares her vision for the company and for AI in biotech

January 15, 2026

Recursion's new CEO Najat Khan shares her vision for leveraging an end-to-end AI platform to deliver differentiated medicines at scale.

SF Healthcare Week: Astellas Pharma CEO Naoki Okamura describes the type of assets the company looks for externally, and covers key internal pipeline assets

January 15, 2026

Astellas CEO outlines its strategy: leveraging a biology-first R&D approach and key assets to drive growth and offset the 2027 Xtandi patent cliff.

SF Healthcare Week: Beam's CEO John Evans shares an update on based editing for alpha-1 antitrypsin deficiency, sickle cell disease, and more

January 12, 2026

Beam Therapeutics' CEO discusses an accelerated FDA pathway for its alpha-1 base editor, a planned BLA filing for its sickle cell therapy, and future platform expansion.

SF Healthcare Week: Vera Therapeutics’ announced this week that the FDA accepted the company’s filing for atacicept, a potential new treatment for IgA Nephropathy

January 12, 2026

Vera Therapeutics' atacicept for IgA Nephropathy gets FDA priority review. With strong Phase 3 data, the company prepares for a July US launch.

Mizuho Senior Biotech Analyst Salim Syed highlights key companies in the news he covers heading into the new year

January 7, 2026

Mizuho's Salim Syed on key biotech catalysts: Eyes on BridgeBio's launch, Cytokinetics' data, Vaxite's macro shift, and Biogen/Arcus value.

William Blair Senior Biotech Analyst Andy Hsieh shares an overview of the obesity space heading into 2026

December 30, 2025

The obesity drug market heats up as Novo's oral Wegovy challenges injectables, but its strict dosing regimen may cede ground to Lilly's orfoglipron.

A deep dive discussion on Abivax with Truist Senior Biotech Analyst Gregory Renza

December 29, 2025

Deep dive on Abivax: Analyst Gregory Renza discusses the upcoming maintenance trial, Obafazimod's risks, and intense M&A speculation.

Create Medicines' platform allows it to program CARs into multiple immune cell types inside the body, and is redosable. While this includes CAR-T, they believe that "in vivo is more than T-cells."

December 12, 2025

Create Medicines engineers myeloid, T, & NK cells in vivo using a versatile LNP/RNA platform, enabling repeat dosing for solid tumors and beyond.

The leaders of London based LabGenius Therapeutics discuss a recent ESMO IO poster for their Nectin-4 x CD3 T-cell engager, and a new expanded collaboration with Sanofi on antibody optimization

December 11, 2025

LabGenius uses ML to design safer, non-intuitive multi-specific antibodies, partnering with Sanofi and advancing its lead Nectin-4 candidate.

Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today

December 11, 2025

Medra raised $52M to build "physical AI scientists," combining AI reasoning with adaptive robotics to automate and scale scientific discovery.

ASH 2025: Kelonia Therapeutics presented convincing late-breaking data at ASH today from its initial patients in multiple myeloma suggesting that in vivo CAR-T is on track to be a next innovation

December 9, 2025

Colonia Therapeutics' in vivo CAR-T shows deep MRD-negative responses in myeloma without chemo, a potential paradigm shift in cancer therapy.

ASH 2025: Corvus CEO Richard Miller believes that ITK inhibitors can have the same broad impact on T-cell diseases as BTK inhibitors have had on B-cell diseases - he would know

December 9, 2025

Corvus Pharma's ITK inhibitor, soquelitinib, shows a remarkable 28-month survival in T-cell lymphoma and is expanding into atopic dermatitis.

ASH 2025: Nurix CEO Arthur Sands discusses his company's BTK degrader data at ASH, and highlights the benefits of degraders more broadly in oncology and I&I

December 8, 2025

Neurix's BTK degrader shows 22.1-month PFS in late-line CLL. CEO discusses strategy for degraders to displace inhibitors across medicine.

ASH 2025: Orca Bio has an April 6th PDUFA date from FDA for its cell therapy product, Orca-T, that aims to solve the problem of treatment-related toxicities that come with stem cell transplants

December 7, 2025

Orca Bio's Orca T therapy aims to replace stem cell transplants for blood cancer, using regulatory T-cells to prevent GVHD. PDUFA is April 6.

Two veterans from MPM have launched a new VC firm that will focus on investing in the I&I space - and it will leverage collaborations with disease specific philanthropies

December 5, 2025

Vi Ventures is launching a new fund for the I&I revolution, leveraging a unique model of partnering with patient foundations to de-risk drug development.

Oxford, UK based Accession Therapeutics raised $40M from existing investors today to further develop its precision viral delivered immunotherapies. The first program induces cancer cells to make PD-L1

December 4, 2025

Accession Therapeutics tackles solid tumors with armed, de-targeted viruses that deliver potent drugs locally, avoiding systemic toxicity.

Jefferies London: Ipsen has done a string of deals over recent years, including acquiring ImCheck last month. CEO David Loew says the company has billions in firepower to do more

November 19, 2025

Ipsen's CEO discusses a growth strategy fueled by neurotoxin innovation, rare disease drug expansion, and over €3B for M&A in oncology.

Jefferies London: Terns' CEO Amy Burroughs previews the company's upcoming ASH presentation for the allosteric BCR::ABL1 inhibitor tern-701 in relapsed/refractory cml

November 19, 2025

Terns Pharmaceuticals' TURNS-701 shows 'best in disease' potential for CML with an unprecedented 64% MMR rate and superior safety profile.

Jefferies London: Affinity Asset Advisors' Patrick Nosker shares a public investor's perspective on biotech and walks us through a few of his firm's top positions

November 19, 2025

Investor Patrick Nosker on biotech's recovery: M&A will continue, driven by pharma needs. Key insights on Xenon, Madrigal, and Alkermes.

Jefferies London: Jefferies Global Chairman of Healthcare Philip Ross discusses the environment for biotech and deals

November 18, 2025

Jefferies' Philip Ross on biotech: M&A thrives on pharma's growth needs, but P&L capacity, not cash, is the real constraint. Outlook is bullish.

Jefferies London: Chief Scientific Officer Tony Wood covers the latest highlights in GSK's pipeline, including oncology, respiratory, and inflammation

November 18, 2025

GSK's CSO Tony Wood outlines their R&D strategy: rebuilding oncology, innovating with long-acting antibodies, and targeted bolt-on acquisitions.

Jefferies London: Protagonist Therapeutics CEO Dinesh Patel responds to takeout speculation and discusses the company's programs and culture of partnering

November 18, 2025

Protagonist Therapeutics' CEO on M&A buzz, lucrative J&J/Takeda deals, and a new oral triple-agonist for the competitive obesity market.

Jefferies London: Jefferies M&A Banker Chris Roop shares his take on the environment for deals in biotech

November 17, 2025

Biopharma M&A is booming, driven by pharma's patent cliffs. Expect more large deals in 2026, fueling capital recycling & industry growth.

Legend Biotech CEO Ying Huang shares a post-earnings update from the company's new R&D Center in Philadelphia

November 13, 2025

Legend Biotech opens a new Philly R&D lab, boosts manufacturing to 10k doses/yr, and celebrates 2nd-line CARVICTI approval in US/EU.

Apogee will have at lest four key trial readouts for its half-life optimized IL-13 program next year, including monotherapy trials and in combination with OX40L and TSLP.

November 12, 2025

Apogee Therapeutics is developing extended half-life antibodies for I&I diseases, aiming to shift dosing from bi-weekly to quarterly or longer.

Celcuity release what it believes is practice changing breast cancer data with its multi-target PAM inhibitor. Co-Founder & CEO Brian Sullivan describes why he believes the data is so important

November 11, 2025

Cellcuity's gadotolitinib shows historic efficacy in hard-to-treat wild-type HR+/HER2- breast cancer by comprehensively inhibiting the PAM pathway.

Aardvark Therapeutics' approach to obesity is to inhibit hunger (vs appetite). It has a key pivotal trial scheduled to read in Prader-Willi syndrome early next year, and is also working on weight loss

November 11, 2025

Aardvark Therapeutics targets hunger via a novel gut-brain signaling drug, advancing a Phase 3 trial for Prader-Willi syndrome due in '26.

Adaptyx announced $14M in additional seed financing to fund the development of a continuous health monitoring device that aims to track small molecules, electrolytes, hormones, drugs, and proteins

November 10, 2025

Adaptix is creating a wearable biosensor patch for continuous, real-time biochemical monitoring, set to revolutionize clinical care and wellness.

Synthekine presented data at SITC on its α/β-IL-2 receptor biased partial agonist showing a 53% response rate in PD-L1 negative nonsquamous NSCLC

November 8, 2025

Synthakyne's alpha-beta biased IL-2 shows >50% response rate in hard-to-treat lung cancer, promising a safer, more targeted IO therapy.

Menlo Ventures published a report showing that the healthcare industry is the leading adopter of AI - one of the co-authors shares the key takeaways

November 5, 2025

Healthcare's AI boom: A new report reveals surprisingly fast adoption, driven by organic need, with startups outmaneuvering incumbents.

BIO-Europe 2025: Spain based ARTHEx Biotech is a European player in the DM1 space, and believes its microRNA strategy offers a dual benefit that it says is unique to the field

November 4, 2025

Arthex Biotech is developing ATX01 for Myotonic Dystrophy Type 1, using a novel dual-action RNA approach to target both muscle and CNS.

BIO-Europe 2025: Step Pharma has 'followed the genetics' to be the first company to target CTPS1 inhibition for cancer - CEO Andrew Parker walks us through this unique science

November 4, 2025

Step Pharma pioneers a first-in-class CTPS1 inhibitor for oncology, leveraging synthetic lethality for a targeted, safe therapeutic approach.

BIO-Europe 2025: Switzerland based ReproNovo is focused on reproductive health - with two clinical stage assets and three indications it is going after

November 3, 2025

Repro Novo is advancing two Phase 2 assets in reproductive health for male infertility and adenomyosis, funded by a $65M Series A.